<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4019">
  <stage>Registered</stage>
  <submitdate>14/06/2013</submitdate>
  <approvaldate>14/06/2013</approvaldate>
  <nctid>NCT01904292</nctid>
  <trial_identification>
    <studytitle>A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis</studytitle>
    <scientifictitle>A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2012-003490-26</secondaryid>
    <secondaryid>WA28118</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Juvenile Idiopathic Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tocilizumab

Experimental: Tocilizumab - Participants will receive SC dose of tocilizumab based on body weight; participants with &lt;30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =&gt;30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.


Treatment: drugs: Tocilizumab
Subcutaneous 162 mg dose QW or Q2W for 52 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Tocilizumab</outcome>
      <timepoint>Age &lt;2 years: 0 hours(h) on Days(D) 0,84; on D5,14,42,70,85,88,98,182,266, 364. Weight &lt;30kg, Age&gt;=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266, 364</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Tocilizumab</outcome>
      <timepoint>Age &lt;2 years: 0h on D0,84; on D5,14,42,70,85,88,98,182,266,364. Weight &lt;30 kg, Age &gt;=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30 kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266,364</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics: Minimum Plasma Concentration (Cmin) of Tocilizumab</outcome>
      <timepoint>Weight &lt;30 kg: predose (0h) on Days 0 and 84. Weight &gt;= 30 kg: predose (0h) on Days 0 and 91</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics: Serum Interleukin-6 (IL6) Levels</outcome>
      <timepoint>Age&lt;2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight &lt;30 kg, Age &gt;=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics: Soluble IL-6 Receptor (sIL-6R) Levels</outcome>
      <timepoint>Age&lt;2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight &lt;30 kg, Age &gt;=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics: Serum C-Reactive Protein (CRP) Levels</outcome>
      <timepoint>Age &lt;2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight &lt;30 kg, Age &gt;=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight &gt;=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics: Serum Erythrocyte Sedimentation Rate (ESR)</outcome>
      <timepoint>Age &lt;2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight &lt;30 kg, Age &gt;=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight &gt;=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics: Percentage of Participants with Anti-Tocilizumab Antibodies</outcome>
      <timepoint>Age &lt;2 years: Days 0, 84, 182, 266, 364. Weight &lt;30 kg, Age &gt;=2 years: Days 0, 84, 182, 266, 364. Weight &gt;=30 kg: Days 0, 91, 182, 266, 364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Percentage of Participants with At Least 1 Adverse Event</outcome>
      <timepoint>57 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of sJIA according to the International League of Associations for
             Rheumatology (ILAR) classification

          -  History of inadequate clinical response (in the opinion of the treating physician) to
             Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids

          -  If a participant has received previous treatment with any biologic agents other than
             tocilizumab, these must have been discontinued according to the timelines defined by
             protocol prior to the baseline visit

          -  Participants currently receiving tocilizumab by the intravenous (IV) route of
             administration and with well-controlled disease do not require a period of
             discontinuation of IV tocilizumab and should have their first dose of SC tocilizumab
             administered on the date that their next IV tocilizumab infusion would be due

          -  Concurrent treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs) including
             methotrexate (MTX), NSAIDs, and oral corticosteroids are permitted at the discretion
             of the investigator

          -  Participants of reproductive potential must be willing to use highly effective
             contraceptive methods</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior discontinuation of IV tocilizumab because of inadequate clinical response or
             safety events (including hypersensitivity)

          -  Participants with poorly controlled disease (in the opinion of the treating physician)
             despite current treatment with IV tocilizumab

          -  sJIA that is well controlled by any treatment agent other than tocilizumab (Juvenile
             Arthritis Disease Activity Score of 71 Joints [JADAS-71] less than or equal to [&lt;=]
             3.8 with no fever)

          -  Participants who are wheelchair-bound or bedridden

          -  Any other auto-immune, rheumatic disease, or overlapping syndrome other than sJIA

          -  Lack of recovery from recent surgery or an interval of &lt;6 weeks since surgery at the
             time of the screening visit

          -  Females who are pregnant, lactating, or intending to become pregnant during study
             conduct

          -  Any significant concurrent medical or surgical condition that would jeopardize the
             participant's safety or ability to complete the study

          -  Known Human Immunodeficiency Virus (HIV) infection or other acquired forms of immune
             compromise or inborn conditions characterized by a compromised immune system

          -  History of alcohol, drug, or chemical abuse within 6 months of screening

          -  Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal
             infection or any major episode of infection requiring hospitalization or treatment
             during screening or treatment with IV antibiotics completed within 4 weeks of the
             screening visit or oral antibiotics completed within 2 weeks of the screening visit

          -  History of atypical tuberculosis (TB) or active TB requiring treatment within 2 years
             prior to screening visit

          -  Positive TB test at screening unless treated with anti-TB therapy for at least 4 weeks
             prior to receiving study drug

          -  History of reactivation or new onset of a systemic infection such as herpes zoster or
             Epstein-Barr virus within 2 months of the screening visit

          -  Hepatitis B surface antigen or hepatitis C antibody positivity or chronic viral or
             autoimmune hepatitis

          -  History of concurrent serious gastrointestinal disorders such as ulcer or inflammatory
             bowel disease, Crohn's disease, ulcerative colitis, or other symptomatic lower
             gastrointestinal conditions

          -  History of or current cancer or lymphoma

          -  Uncontrolled diabetes mellitus with elevated glycosylated hemoglobin

          -  Macrophage activation syndrome (MAS) within 3 months of the screening visit

          -  Inadequate hematologic, renal or liver function</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>15/08/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>52</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>13/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Westmead Hospital; Paediatric Rheumatology - Westmead</hospital>
    <hospital>Royal Children'S Hospital; Paediatric Rheumatology - Parkville</hospital>
    <postcode>2145 - Westmead</postcode>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Cordoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremlin BicÃªtre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sankt Augustin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Liguria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Miexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and
      safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile
      Idiopathic Arthritis (sJIA). Participants with body weight less than (&lt;) 30 kilograms (kg)
      will receive subcutaneous (SC) tocilizumab dose every 2 weeks (Q2W) and participants with
      body weight greater than or equal to (&gt;=) 30 kg will receive weekly (QW), for 52 weeks.
      Tocilizumab was administered every 10 days until pre-planned interim analysis was performed
      and changed to Q2W in participants with body weight &lt;30 kg.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01904292</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>